Selected research
Industry Research
Swine Erysipelas Vaccine Industry Research Report 2026
Market perspective
The global Swine Erysipelas Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Swine Erysipelas Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Swine Erysipelas Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Swine Erysipelas Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Swine Erysipelas Vaccine include CAHIC, Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd., Qilu Animal Health, Merck, Jiujiang Bomeilai Biological, Jilin Zhengye Biological, Hunan Zhong'an Biological Pharmaceutical Co., Ltd., Chengdu Tianbang Biology and Zoetis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Swine Erysipelas Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (K Doses), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Doses) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Swine Erysipelas Vaccine Market by Company
CAHIC
Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd.
Qilu Animal Health
Merck
Jiujiang Bomeilai Biological
Jilin Zhengye Biological
Hunan Zhong'an Biological Pharmaceutical Co., Ltd.
Chengdu Tianbang Biology
Zoetis
Boehringer Ingelheim
Swine Erysipelas Vaccine Segment by Type
Live
Inactivated
Swine Erysipelas Vaccine Segment by Application
Pharmacy
Online Sale
Others
Swine Erysipelas Vaccine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Swine Erysipelas Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Swine Erysipelas Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Swine Erysipelas Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Swine Erysipelas Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Swine Erysipelas Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Swine Erysipelas Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Live
- Inactivated
Applications
- Pharmacy
- Online Sale
- Others
Companies covered
- CAHIC
- Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd.
- Qilu Animal Health
- Merck
- Jiujiang Bomeilai Biological
- Jilin Zhengye Biological
- Hunan Zhong'an Biological Pharmaceutical Co., Ltd.
- Chengdu Tianbang Biology
- Zoetis
- Boehringer Ingelheim
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Swine Erysipelas Vaccine Market Size (2021-2032)
- 2.2.2 Global Swine Erysipelas Vaccine Sales (2021-2032)
- 2.2.3 Global Swine Erysipelas Vaccine Market Average Price (2021-2032)
- 2.3 Swine Erysipelas Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Live
- 2.3.3 Inactivated
- 2.4 Swine Erysipelas Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Pharmacy
- 2.4.3 Online Sale
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Swine Erysipelas Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Swine Erysipelas Vaccine Sales (K Doses) of Manufacturers (2021-2026)
- 3.3 Global Swine Erysipelas Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Swine Erysipelas Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Swine Erysipelas Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Swine Erysipelas Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Swine Erysipelas Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Swine Erysipelas Vaccine, Established Date
- 3.9 Global Swine Erysipelas Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 CAHIC
- 4.1.1 CAHIC Company Information
- 4.1.2 CAHIC Business Overview
- 4.1.3 CAHIC Swine Erysipelas Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 CAHIC Swine Erysipelas Vaccine Product Portfolio
- 4.1.5 CAHIC Recent Developments
- 4.2 Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd.
- 4.2.1 Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd. Company Information
- 4.2.2 Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd. Business Overview
- 4.2.3 Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd. Swine Erysipelas Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd. Swine Erysipelas Vaccine Product Portfolio
- 4.2.5 Zhejiang Shihua Nuo Beiwei Biotechnology Co., Ltd. Recent Developments
- 4.3 Qilu Animal Health
- 4.3.1 Qilu Animal Health Company Information
- 4.3.2 Qilu Animal Health Business Overview
- 4.3.3 Qilu Animal Health Swine Erysipelas Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Qilu Animal Health Swine Erysipelas Vaccine Product Portfolio
- 4.3.5 Qilu Animal Health Recent Developments
- 4.4 Merck
- 4.4.1 Merck Company Information
- 4.4.2 Merck Business Overview
- 4.4.3 Merck Swine Erysipelas Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Merck Swine Erysipelas Vaccine Product Portfolio
- 4.4.5 Merck Recent Developments
- 4.5 Jiujiang Bomeilai Biological
- 4.5.1 Jiujiang Bomeilai Biological Company Information
- 4.5.2 Jiujiang Bomeilai Biological Business Overview
- 4.5.3 Jiujiang Bomeilai Biological Swine Erysipelas Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Jiujiang Bomeilai Biological Swine Erysipelas Vaccine Product Portfolio
- 4.5.5 Jiujiang Bomeilai Biological Recent Developments
- 4.6 Jilin Zhengye Biological
- 4.6.1 Jilin Zhengye Biological Company Information
- 4.6.2 Jilin Zhengye Biological Business Overview
- 4.6.3 Jilin Zhengye Biological Swine Erysipelas Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Jilin Zhengye Biological Swine Erysipelas Vaccine Product Portfolio
- 4.6.5 Jilin Zhengye Biological Recent Developments
- 4.7 Hunan Zhong'an Biological Pharmaceutical Co., Ltd.
- 4.7.1 Hunan Zhong'an Biological Pharmaceutical Co., Ltd. Company Information
- 4.7.2 Hunan Zhong'an Biological Pharmaceutical Co., Ltd. Business Overview
- 4.7.3 Hunan Zhong'an Biological Pharmaceutical Co., Ltd. Swine Erysipelas Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Hunan Zhong'an Biological Pharmaceutical Co., Ltd. Swine Erysipelas Vaccine Product Portfolio
- 4.7.5 Hunan Zhong'an Biological Pharmaceutical Co., Ltd. Recent Developments
- 4.8 Chengdu Tianbang Biology
- 4.8.1 Chengdu Tianbang Biology Company Information
- 4.8.2 Chengdu Tianbang Biology Business Overview
- 4.8.3 Chengdu Tianbang Biology Swine Erysipelas Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Chengdu Tianbang Biology Swine Erysipelas Vaccine Product Portfolio
- 4.8.5 Chengdu Tianbang Biology Recent Developments
- 4.9 Zoetis
- 4.9.1 Zoetis Company Information
- 4.9.2 Zoetis Business Overview
- 4.9.3 Zoetis Swine Erysipelas Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Zoetis Swine Erysipelas Vaccine Product Portfolio
- 4.9.5 Zoetis Recent Developments
- 4.10 Boehringer Ingelheim
- 4.10.1 Boehringer Ingelheim Company Information
- 4.10.2 Boehringer Ingelheim Business Overview
- 4.10.3 Boehringer Ingelheim Swine Erysipelas Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Boehringer Ingelheim Swine Erysipelas Vaccine Product Portfolio
- 4.10.5 Boehringer Ingelheim Recent Developments
5 Global Swine Erysipelas Vaccine Market Scenario by Region
- 5.1 Global Swine Erysipelas Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Swine Erysipelas Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Swine Erysipelas Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Swine Erysipelas Vaccine Sales by Region: 2027-2032
- 5.3 Global Swine Erysipelas Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Swine Erysipelas Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Swine Erysipelas Vaccine Revenue by Region: 2027-2032
- 5.4 North America Swine Erysipelas Vaccine Market Facts & Figures by Country
- 5.4.1 North America Swine Erysipelas Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Swine Erysipelas Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Swine Erysipelas Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Swine Erysipelas Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Swine Erysipelas Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Swine Erysipelas Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Swine Erysipelas Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Swine Erysipelas Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Swine Erysipelas Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Swine Erysipelas Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Swine Erysipelas Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Swine Erysipelas Vaccine Market Facts & Figures by Country
- 5.7.1 South America Swine Erysipelas Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Swine Erysipelas Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Swine Erysipelas Vaccine Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Swine Erysipelas Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Swine Erysipelas Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Swine Erysipelas Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Swine Erysipelas Vaccine Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Swine Erysipelas Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Swine Erysipelas Vaccine Sales by Type (2021-2032) & (K Doses)
- 6.1.2 Global Swine Erysipelas Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Swine Erysipelas Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Swine Erysipelas Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Swine Erysipelas Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Swine Erysipelas Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Swine Erysipelas Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Swine Erysipelas Vaccine Sales by Application (2021-2032) & (K Doses)
- 7.1.2 Global Swine Erysipelas Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Swine Erysipelas Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Swine Erysipelas Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Swine Erysipelas Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Swine Erysipelas Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Swine Erysipelas Vaccine Value Chain Analysis
- 8.1.1 Swine Erysipelas Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Swine Erysipelas Vaccine Production Mode & Process
- 8.2 Swine Erysipelas Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Swine Erysipelas Vaccine Distributors
- 8.2.3 Swine Erysipelas Vaccine Customers
9 Global Swine Erysipelas Vaccine Analyzing Market Dynamics
- 9.1 Swine Erysipelas Vaccine Industry Trends
- 9.2 Swine Erysipelas Vaccine Industry Drivers
- 9.3 Swine Erysipelas Vaccine Industry Opportunities and Challenges
- 9.4 Swine Erysipelas Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst